Insilico Medicine: Chairman Plans Up to HKD16.00 Million Share Purchase in September 2026

Bulletin Express08:22

Insilico Medicine Cayman TopCo (Insilico Medicine) disclosed that its Chairman, Executive Director, Chief Executive Officer, and Chief Business Officer, Dr. Aleksandrs Zavoronkovs, will initiate an open-market share purchase program in September 2026. The “Share Increasing Plan” authorizes Dr. Zavoronkovs to acquire additional company shares with personal funds of up to HKD 16.00 million.

The company noted that Dr. Zavoronkovs previously participated in Insilico Medicine’s Series D financing round in 2022, underscoring his continuing commitment to the group’s long-term prospects. Insilico Medicine affirmed that, based on current information, the planned purchases will not affect its public float requirements under Hong Kong Stock Exchange regulations.

Management emphasized that the initiative reflects confidence in the company’s future development and investment value. The board also reminded shareholders and potential investors to exercise caution when trading the company’s securities and highlighted that the announcement contains forward-looking statements which remain subject to uncertainty. The disclosed financial data have not been audited or reviewed by external auditors.

The voluntary announcement was issued on 4 September 2026 and signed by Dr. Zavoronkovs on behalf of the board.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1142982745?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-04 08:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142982745","market":"hk","top_or_hot":-1,"title":"Insilico Medicine: Chairman Plans Up to HKD16.00 Million Share Purchase in September 2026","media":"Bulletin Express","content":"<p>Insilico Medicine Cayman TopCo (Insilico Medicine) disclosed that its Chairman, Executive Director, Chief Executive Officer, and Chief Business Officer, Dr. Aleksandrs Zavoronkovs, will initiate an open-market share purchase program in September 2026. The “Share Increasing Plan” authorizes Dr. Zavoronkovs to acquire additional company shares with personal funds of up to HKD 16.00 million.</p>\n<p>The company noted that Dr. Zavoronkovs previously participated in Insilico Medicine’s Series D financing round in 2022, underscoring his continuing commitment to the group’s long-term prospects. Insilico Medicine affirmed that, based on current information, the planned purchases will not affect its public float requirements under Hong Kong Stock Exchange regulations.</p>\n<p>Management emphasized that the initiative reflects confidence in the company’s future development and investment value. The board also reminded shareholders and potential investors to exercise caution when trading the company’s securities and highlighted that the announcement contains forward-looking statements which remain subject to uncertainty. The disclosed financial data have not been audited or reviewed by external auditors.</p>\n<p>The voluntary announcement was issued on 4 September 2026 and signed by Dr. Zavoronkovs on behalf of the board.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insilico Medicine: Chairman Plans Up to HKD16.00 Million Share Purchase in September 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsilico Medicine: Chairman Plans Up to HKD16.00 Million Share Purchase in September 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-04 08:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Insilico Medicine Cayman TopCo (Insilico Medicine) disclosed that its Chairman, Executive Director, Chief Executive Officer, and Chief Business Officer, Dr. Aleksandrs Zavoronkovs, will initiate an open-market share purchase program in September 2026. The “Share Increasing Plan” authorizes Dr. Zavoronkovs to acquire additional company shares with personal funds of up to HKD 16.00 million.</p>\n<p>The company noted that Dr. Zavoronkovs previously participated in Insilico Medicine’s Series D financing round in 2022, underscoring his continuing commitment to the group’s long-term prospects. Insilico Medicine affirmed that, based on current information, the planned purchases will not affect its public float requirements under Hong Kong Stock Exchange regulations.</p>\n<p>Management emphasized that the initiative reflects confidence in the company’s future development and investment value. The board also reminded shareholders and potential investors to exercise caution when trading the company’s securities and highlighted that the announcement contains forward-looking statements which remain subject to uncertainty. The disclosed financial data have not been audited or reviewed by external auditors.</p>\n<p>The voluntary announcement was issued on 4 September 2026 and signed by Dr. Zavoronkovs on behalf of the board.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1142982745","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142982745","pubTimestamp":1788481337,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Insilico Medicine Cayman TopCo (Insilico Medicine) disclosed that its Chairman, Executive Director, Chief Executive Officer, and Chief Business Officer, Dr. Aleksandrs Zavoronkovs, will initiate an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"Insilico Medicine：董事长计划于 2026 年 9 月购买至多 1,600 万港元的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"Insilico Medicine Cayman TopCo (Insilico Medicine) disclosed that its Chairman, Executive Director, Chief Executive Officer, and Chief Business Officer, Dr. Aleksandrs Zavoronkovs, will initiate an open-market share purchase program in September 2026. The “Share Increasing Plan” authorizes Dr. Zavoronkovs to acquire additional company shares with personal funds of up to HKD 16.00 million.\nThe company noted that Dr. Zavoronkovs previously participated in Insilico Medicine’s Series D financing round in 2022, underscoring his continuing commitment to the group’s long-term prospects. Insilico Medicine affirmed that, based on current information, the planned purchases will not affect its public float requirements under Hong Kong Stock Exchange regulations.\nManagement emphasized that the initiative reflects confidence in the company’s future development and investment value. The board also reminded shareholders and potential investors to exercise caution when trading the company’s securities and highlighted that the announcement contains forward-looking statements which remain subject to uncertainty. The disclosed financial data have not been audited or reviewed by external auditors.\nThe voluntary announcement was issued on 4 September 2026 and signed by Dr. Zavoronkovs on behalf of the board.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1142982745","isCrawlerRequest":true}